Printer Friendly

VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY: ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT

 VESTAR FILES COUNTERCLAIM VS. THE LIPOSOME COMPANY:
 ALLEGES THAT PATENT IS INVALID AND DENIES INFRINGEMENT
 SAN DIMAS, Calif. July 15 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that it has filed a counterclaim in the U.S. District Court stating that The Liposome Company's (NASDAQ: LIPO) patent 4,229,360 is invalid. Vestar has denied that it is infringing this patent, and has asked that the court dismiss the infringement complaint against Vestar, declare The Liposome Company's patent to be unenforceable and award Vestar all costs associated with these legal proceedings.
 The Vestar counterclaim states that Patent 4,229,360 is not valid because the claimed invention is not novel and is not properly described in the patent and claims. Vestar has also charged The Liposome Company with making misleading and inaccurate statements regarding this patent to the U.S. Patent and Trademark Office.
 Vestar management stated that the counterclaim is consistent with its policy of pursuing all available means to contest the allegations in a patent infringement complaint filed by The Liposome Company on June 23, 1992, alleging a violation of its patent regarding the lyophilization of liposomes. Vestar manufactures its AmBisome(R) product using its own proprietary manufacturing techniques, including a lyophilization process that utilizes technology covered by U.S. Patent 4,857,319 to which Vestar has exclusive rights.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds. Since 1989, Vestar has been marketing AmBisome, a liposomal formulation of amphotericin B, in Europe to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is in development as Vestar's second major product.
 -0- 7/15/92
 /CONTACT: Adam Cochran, M.S., J.D., senior patent counsel, Vestar Inc., 714-394-4000/714-394-4132, or Marcia A. Kean of Feinstein Partners, 617-577-8110, for Vestar/
 (VSTR LIPO) CO: Vestar Inc.; The Liposome Company ST: California IN: MTC SU:


TM -- NE002 -- 9381 07/15/92 08:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 15, 1992
Words:354
Previous Article:ROLLINS ENVIRONMENTAL SERVICES REPORTS THIRD QUARTER RESULTS; REVENUES UP 18 PERCENT, EARNINGS UP 69 PERCENT
Next Article:APPLE COMPUTER SPONSORS OLYMPICS DESIGN EXHIBITION
Topics:


Related Articles
THE LIPOSOME COMPANY SUES VESTAR; SUIT CHARGES VESTAR'S AMBISOME INFRINGES LIPOSOME'S PATENT
VESTAR TO REVIEW LEGAL DOCUMENTS; BELIEVES PATENTS ARE SECURE
VESTAR EXPRESSES CONFIDENCE IN PATENT POSITION; WILL VIGOROUSLY CONTEST ALL INFRINGEMENT ALLEGATIONS
VESTAR FILES SUIT AGAINST LIPOSOME TECHNOLOGY, INC.
COURT FINDS VESTAR DOES NOT INFRINGE LTI PATENT
LIPOSOME TECHNOLOGY, INC. ANNOUNCES JUDGMENT
SIBIA NEUROSCIENCES, INC. ANNOUNCES COUNTERCLAIM FILED BY CADUS PHARMACEUTICAL CORPORATION IN PATENT SUIT
Valentis announces settlement of PEG-liposome patent infringement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters